Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

C0430000

Captopril

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

N-[(S)-3-Mercapto-2-methylpropionyl]-L-prolin

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C9H15NO3S
CAS-Nummer:
62571-86-2
Molekulargewicht:
217.29
Beilstein:
477887
MDL-Nummer:
MFCD00168073
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329774790
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

captopril

Hersteller/Markenname

EDQM

mp (Schmelzpunkt)

104-108 °C (lit.)

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

InChI

1S/C9H15NO3S/c1-6(5-14)8(11)10-4-2-3-7(10)9(12)13/h6-7,14H,2-5H2,1H3,(H,12,13)/t6-,7+/m1/s1

InChIKey

FAKRSMQSSFJEIM-RQJHMYQMSA-N

Angaben zum Gen

human ... ACE(1636)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Captopril EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem./physiol. Wirkung

Angiotensin Converting Enzyme-Hemmer. Hemmt die Bildung von Angiotensin II, einem bioaktiven Peptid, das die Angionese stimuliert und die Mikrogefäßdichte erhöht.

Verpackung

Dieses Produkt wird, wie von der entsprechenden Pharmakopöe geliefert, angeboten. Die aktuellen Mengeneinheiten finden Sie im Referenzsubstanzen-Katalog der EDQM.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

1091200

Captopril, United States Pharmacopeia (USP) Reference Standard

1091221

Captoprildisulfid, United States Pharmacopeia (USP) Reference Standard

Y0000435

Captopril Unreinheit E, European Pharmacopoeia (EP) Reference Standard

Y0001182

Captopril für die Systemeignung, European Pharmacopoeia (EP) Reference Standard

Y0001221

Captopril Unreinheit D, European Pharmacopoeia (EP) Reference Standard

Y0001219

Captopril Unreinheit B, European Pharmacopoeia (EP) Reference Standard

Y0001220

Captopril Unreinheit C, European Pharmacopoeia (EP) Reference Standard

Y0001450

Captopril Unreinheit J, European Pharmacopoeia (EP) Reference Standard

BP538

Captopril, British Pharmacopoeia (BP) Reference Standard

BP500

Captoprildisulfid, British Pharmacopoeia (BP) Reference Standard

Piktogramme

Health hazard
GHS08

Signalwort

Danger

H-Sätze

H341,H360F

Gefahreneinstufungen

Muta. 2 - Repr. 1B

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 2

1 of 2

Natriumnitrat ReagentPlus®, ≥99.0%

Sigma-Aldrich

S5506

Natriumnitrat

Kaliumhydrogenphthalat BioXtra, ≥99.95%

Sigma-Aldrich

P1088

Kaliumhydrogenphthalat

Antonio C M Camargo et al.
Toxicon : official journal of the International Society on Toxinology, 59(4), 516-523 (2011-08-13)
The identification of novel endogenous and exogenous molecules acting in the complex mechanism of regulating the vascular tonus has always been of great interest. The discovery of bradykinin (1949) and the bradykinin-potentiating peptides (1965) had a pivotal influence in the
A O Nur et al.
International journal of pharmaceutics, 194(2), 139-146 (2000-02-29)
The development of oral sustained or controlled release dosage form of captopril has been an interested topic of research for a long period of time. Difficulties encountered with such topic based on the fact that the drug is freely water
R I Ogilvie et al.
The Canadian journal of cardiology, 14(8), 1025-1033 (1998-09-17)
Twenty-four splenectomized dogs were subjected to rapid right ventricular pacing (RRVP) at 250 beats/min for five weeks. During the final three weeks, four groups six dogs were untreated or treated with captopril alone, with the angiotensin II type 1 (AT1)
A Schattner et al.
The American journal of the medical sciences, 322(4), 236-240 (2001-10-27)
Two elderly patients, treated with captopril for left ventricular dysfunction and diabetes, developed severe cholestatic jaundice for which no alternative explanation could be found. The jaundice resolved completely after discontinuation of the drug. A review of the literature identifies a
Javed Mahmood et al.
International journal of radiation oncology, biology, physics, 89(4), 722-728 (2014-05-29)
To investigate the outcome of suppression of the renin angiotensin system using captopril combined with an antioxidant (Eukarion [EUK]-207) for mitigation of radiation-induced lung damage in rats. The thoracic cavity of female Sprague-Dawley rats was irradiated with a single dose
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.